Medicare National Payment Rate Confirmation

Verici Dx PLC

08 January 2024

 

Verici Dx plc

("Verici Dx" or the "Company") 

Medicare National Payment Rate for Tutivia™ and Clarava™ Effective as of January 1, 2024

CMS finalises gapfill median rate at $2,650 per test

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that the Centers for Medicare & Medicaid Services ("CMS") released the Clinical Laboratory Fee Schedule ("CLFS") payment rate of $2,650 established through the "gapfill" process for both Tutivia™ (CPT 0320U), its post-transplant test focused upon acute cellular rejection, and Clarava™ (CPT 0319U), its pre-transplant prognosis test for the risk of early acute rejection. This rate is effective as of January 1, 2024.

Having a national payment rate established by CMS represents a step toward securing reimbursement for testing by Medicare, a national health insurance program in the US that covers 63.9 million patients. Gapfill pricing is a method used by CMS to establish a payment rate for clinical diagnostic laboratory tests when no comparable test is priced on the CLFS and involves setting the payment rate for the test at the median of rates established by local Medicare contractors.

Sara Barrington, Chief Executive Officer of Verici Dx, commented: "We are pleased that the pricing for both Tutivia™ and Clarava™ has been confirmed and finalised at the proposed rates. This is another important milestone in our strategy to develop and commercialise a complementary suite of ground-breaking products that offer end-to-end testing for kidney transplant patients and their clinicians."

Enquiries:

Verici Dx	www.vericidx.com
Sara Barrington, CEO	Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser & Broker)	Tel: [phone]
Aubrey Powell / Sam Butcher / Jalini Kalaravy
Walbrook PR Limited	Tel: [phone] or [e-mail]
Stephanie Cuthbert / Sam Allen	Mob: [phone]

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.  The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.  The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

 

END